Condition
Recurrent Platinum-Resistant Ovarian Carcinoma clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Recurrent Platinum-Resistant Ovarian Carcinoma clinical trials that are recruiting, in United States. By phase: Phase 1 (4), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 1Country
Newest Recurrent Platinum-Resistant Ovarian Carcinoma clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| DT2216 with weekly paclitaxel for platinum-resistant ovarian cancer | Phase 1 | Boston, Massachusetts and 2 other locations | Recruiting | May 9, 2025 |
| Using MUC1-activated T cells to treat resistant ovarian cancer | Phase 1 | Scottsdale, Arizona | Recruiting | Jul 1, 2024 |
| Testing drug combinations for recurrent ovarian and endometrial cancer | Phase 1 | Augusta, Georgia and 13 other locations | Recruiting | Jul 18, 2023 |
| Combining pembrolizumab and bevacizumab with an immune booster for recurrent ovarian cancer | Phase 2 | Buffalo, New York and 1 other locations | Recruiting | Feb 9, 2022 |
| Combining Abemaciclib and Olaparib for Women with Recurrent Ovarian Cancer | Phase 1 | Phoenix, Arizona and 26 other locations | Recruiting | Nov 18, 2020 |
All recruiting trials (5)
-
DT2216 with weekly paclitaxel for platinum-resistant ovarian cancer
We are testing whether adding DT2216 to weekly paclitaxel is safe and tolerable for people with recurrent platinum‑resistant ovarian cancer.
-
Using MUC1-activated T cells to treat resistant ovarian cancer
This study is testing a new treatment using specially designed immune cells to see if they can help people with tough-to-treat ovarian cancer feel better and improve their health.
-
Testing drug combinations for recurrent ovarian and endometrial cancer
This study is testing a combination of two drugs to see if they can safely help people with recurrent ovarian and endometrial cancer by blocking tumor growth.
-
Combining pembrolizumab and bevacizumab with an immune booster for recurrent ovarian cancer
This study is testing a new combination of two cancer drugs, pembrolizumab and bevacizumab, with or without an immune booster, to see if it helps people with recurrent ovarian cancer feel better and live longer.
-
Combining Abemaciclib and Olaparib for Women with Recurrent Ovarian Cancer
This study is testing if a combination of two cancer drugs, abemaciclib and olaparib, can help women with recurrent ovarian cancer feel better and fight their disease.
Related topics
Quick answers
How many Recurrent Platinum-Resistant Ovarian Carcinoma clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in United States. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 4, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.